The findings come from a large-scale survey published on Tuesday involving more than 30,500 people in Iceland. After looking at the body’s response to the virus most widely, scientists believe that it hopes to gain immunity through a vaccine.
If a vaccine produces antibodies that are long-lasting, “the expectation is that the immune to this unexpected and highly infectious virus may not host immunity and is similar to most other viral infections,” the scientists wrote in the editorial The study was published in the New England Journal of Medicine.
Researchers are still trying to understand the virus-created immunity. Previous small studies suggested that antibodies were potentially protecting from infection that had faded for weeks, lasting no more than three months.
But researchers involved in the Icelandic report, powered by Reykjavik-based DOCOD genetics, said that previous studies typically observed subjects 28 days after diagnosis while they looked at patients for four months.
They found that one or two months after infection, the body produces a second collection of antibodies that may provide longer protection.
“Infections and vaccines generate two waves of antibodies: the first wave is generated by early short-lived plasma cells, which are ready to populate the systemic circulation, but this wave rapidly decreases after acute infection is resolved,” Scientists Galit Alter and Robert Cedar have written. Vaccination.
“The second wave originates from a small number of long-lived plasma cells that provide long-lived immunity,” they went on.
The scientists behind the study stressed that more research was still needed and not all had the same response to the virus. And it is still unclear whether antibody production will prevent infection.
Recently there have been several reports of patients who became infected again a few months after their first diagnosis.
Researchers also found that about a third of infections in Iceland were among those who reported no symptoms and reported that the rate of infection was 0.3 percent, or about three times as fatal as seasonal flu.
With post wires.